Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N,N dimethyltryptamine - Grey Matters Health

Next Previous
Drug Profile

N,N dimethyltryptamine - Grey Matters Health

Alternative Names: AP-188; DMT - Grey Matters Health; Sprit Molecule

Latest Information Update: 22 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algernon Pharmaceuticals
  • Developer Grey Matters Health
  • Class Anti-inflammatories; Antidepressants; Antipsychotics; Dimethylamines; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules; Tryptamines; Vascular disorder therapies
  • Mechanism of Action Serotonin receptor agonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Stroke; Traumatic brain injuries

Most Recent Events

  • 22 Sep 2026 N,N dimethyltryptamine is still in phase-I trial for Stroke(In volunteers) in Netherlands (IV, Infusion) (Grey Matters Health pipeline; September 2026)
  • 22 Sep 2026 N,N dimethyltryptamine is still in phase-I trial for Traumatic-brain-injuries at the Unknown location (IV, Infusion) (Grey Matters Health pipeline; September 2026)
  • 28 May 2026 No recent reports of development identified for phase-I development in Traumatic-brain-injuries in Unknown (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top